ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Coherus BioSciences Inc

Coherus BioSciences Inc (CHRS)

1.28
-0.03
(-2.29%)
종가: 24 1월 6:00AM
1.3488
0.0688
( 5.37% )
시간외 거래: 8:08AM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
1.3488
매수가
1.31
매도가
1.35
거래량
4,226,071
1.24 일간 변동폭 1.36
0.6655 52주 범위 2.87
market_cap
전일 종가
1.31
개장가
1.33
최근 거래 시간
25
@
1.349
마지막 거래 시간
08:20:49
재정 규모
US$ 5,479,417
VWAP
1.2966
평균 볼륨(3m)
5,267,883
발행 주식
115,213,407
배당수익률
-
주가수익률
-0.63
주당순이익(EPS)
-2.06
매출
257.24M
순이익
-237.89M

Coherus BioSciences Inc 정보

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Coherus BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker CHRS. The last closing price for Coherus BioSciences was US$1.31. Over the last year, Coherus BioSciences shares have traded in a share price range of US$ 0.6655 to US$ 2.87.

Coherus BioSciences currently has 115,213,407 shares in issue. The market capitalisation of Coherus BioSciences is US$150.93 million. Coherus BioSciences has a price to earnings ratio (PE ratio) of -0.63.

CHRS 최신 뉴스

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – –...

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.1312-8.864864864861.481.481.273317833421.3447846CS
4-0.1212-8.244897959181.471.76991.273318174431.4722573CS
120.59278.22410147990.75682.430.665552678831.45286578CS
26-0.3112-18.74698795181.662.430.665535201981.34255893CS
52-1.2512-48.12307692312.62.870.665528986201.65949598CS
156-11.0712-89.140096618412.4214.110.665525201713.75847009CS
260-17.5212-92.852146263918.8723.030.665519099006.59542238CS

CHRS - Frequently Asked Questions (FAQ)

What is the current Coherus BioSciences share price?
The current share price of Coherus BioSciences is US$ 1.3488
How many Coherus BioSciences shares are in issue?
Coherus BioSciences has 115,213,407 shares in issue
What is the market cap of Coherus BioSciences?
The market capitalisation of Coherus BioSciences is USD 150.93M
What is the 1 year trading range for Coherus BioSciences share price?
Coherus BioSciences has traded in the range of US$ 0.6655 to US$ 2.87 during the past year
What is the PE ratio of Coherus BioSciences?
The price to earnings ratio of Coherus BioSciences is -0.63
What is the cash to sales ratio of Coherus BioSciences?
The cash to sales ratio of Coherus BioSciences is 0.58
What is the reporting currency for Coherus BioSciences?
Coherus BioSciences reports financial results in USD
What is the latest annual turnover for Coherus BioSciences?
The latest annual turnover of Coherus BioSciences is USD 257.24M
What is the latest annual profit for Coherus BioSciences?
The latest annual profit of Coherus BioSciences is USD -237.89M
What is the registered address of Coherus BioSciences?
The registered address for Coherus BioSciences is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Coherus BioSciences website address?
The website address for Coherus BioSciences is www.coherus.com
Which industry sector does Coherus BioSciences operate in?
Coherus BioSciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
STBXStarBox Group Holdings Ltd
US$ 1.01
(98.00%)
7.72M
EVAXEvaxion Biotech AS
US$ 5.20
(42.86%)
2.95M
NVNINVNI Group Ltd
US$ 2.0005
(34.26%)
3.02M
TRUGTruGolf Holdings Inc
US$ 0.5801
(19.61%)
2.33M
DWTXDogwood Therapeutics Inc
US$ 15.4999
(16.10%)
2.07M
HYZNHyzon Motors Inc
US$ 0.5503
(-28.72%)
173.67k
VINCVincerx Inc
US$ 0.1084
(-16.03%)
2.17M
SMLRSemier Scientific Inc
US$ 53.10
(-13.16%)
111.11k
ICCTiCoreConnect Inc
US$ 2.391
(-13.05%)
219.15k
DGNXDiginex Ltd
US$ 11.16
(-12.47%)
43.06k
ACONAclarion Inc
US$ 0.049001
(13.43%)
13.58M
HPHHighest Performances Holdings Inc
US$ 0.249
(1.97%)
12.72M
STBXStarBox Group Holdings Ltd
US$ 1.01
(98.00%)
7.72M
HEPAHepion Pharmaceuticals Inc
US$ 0.187
(-6.50%)
7.24M
RIMEAlgorhythm Holdings Inc
US$ 0.0342
(0.29%)
5.98M

CHRS Discussion

게시물 보기
MiamiGent MiamiGent 1 월 전
CHRS It seems to be a set it and forget it play. I'm in.
👍️0
Monksdream Monksdream 1 월 전
CHRS, under $2

👍️0
MiamiGent MiamiGent 1 월 전
CHRS Phase 2 final data on Dec 18th.
Hero or Zero play.
Big short interest 27%. I'm long.
👍️0
MiamiGent MiamiGent 1 월 전
In sometime last week. Like the enthusiasm on this one.

👍️0
glenn1919 glenn1919 1 월 전
CHRS......................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 월 전
CHRS.............................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
Shareing is winning Shareing is winning 2 월 전
Bought 30,000 in early November at .7232 = $21,696 spent, Blah Blah blah I am thinking cast a lot of 20,000 share since this turd is really going nowhere as planned. Maybe repurchase when it gets down to$1.25! 1000 lots at $1.50.
Just tired of watching before the WHALES show up!
👍️0
tw0122 tw0122 2 월 전
Loaded $1.70s again for another flip maybe sees closer to $3 this round
👍️0
glenn1919 glenn1919 2 월 전
CHRS..........................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
axelvento axelvento 2 월 전
Coherus Biosciences has completed the sale of Udenyca, which represents the third segment of its legacy biosimilar business. This deal comes after the company had previously divested other assets, including Cimerli and Yusimry.

The sale of Udenyca, which was projected to fetch around $400 million, or approximately twice its sales, has instead reached a potential value of $558 million, a figure that has positively surprised market observers.

The agreement to sell Udenyca also includes the elimination of Coherus Biosciences' convertible debt, which was due in 2026 and amounted to $230 million. The resolution of this debt is seen as a significant relief for the company, removing a previously contentious issue for shareholders and potentially attracting new investors who are focused on pure-play biotech companies without the looming concern of financing risks.
👍️0
Shareing is winning Shareing is winning 2 월 전
easy reading while you wait FUTURE HOLD GOLD
Coherus BioSciences Inc. (CHRS) Overview
Company Name: Coherus BioSciences, Inc.
Ticker: CHRS
Exchange: Nasdaq Global Market (NasdaqGM)
Region: United States and Canada
Country: United States (US)
Industry: Biotechnology
CEO: Mr. Dennis M. Lanfear
Year Founded: 2010
Headquarters: Redwood City, California

Description:
Coherus BioSciences, Inc. is a biopharmaceutical company focusing on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, and has a pipeline that includes biosimilars of Humira, Avastin, and Lucentis. It also develops Toripalimab, an anti-PD-1 antibody for melanoma treatment in China, among other products. The company has several license agreements with notable firms like Selexis SA, AbbVie, Inc., Pfizer, Inc., and others.

Financial Metrics & Fundamentals
Market Cap: $157.84M
Total Enterprise Value (TEV): $330.03M
Total Revenues: $304.34M

Profitability:

Gross Profit Margin: 44.71%
EBITDA Margin: -38.42%
Operating Margin: -40.16%
Net Profit Margin: -0.15%
Pre-Tax Profit Margin: -0.15%
Per Share:

Revenue per Share: $2.68
EPS Diluted: -$0
Operating Cash Flow per Share: -$0.55
Free Cash Flow per Share: -$0.55
Capital Efficiency:

Return on Total Capital: -28.99%
Return on Capital Employed: -44.16%
Employees:

Total Employees: 235
Revenue per Employee: $1.14M
Gross Profit per Employee: $509.66K
Operating Profit per Employee: -$457.78K
Net Income per Employee: -$1.69K
Valuation:

P/E: -346.05
P/B: -1.79
EV/Sales: 1.08
EV/Gross Profit: 2.43
EV/EBITDA: -2.82
EV/FCF: 3.96
Forward Valuation:

Forward P/E: -5.53
Forward EV/Sales: 1.24
Forward EV/EBITDA: 118.25
Forward EV/FCF: -7.95
Growth:

Revenue 3Y CAGR: -5.76%
Revenue 5Y CAGR: 5.56%
Revenue 10Y CAGR: 27.97%
Diluted EPS 3Y CAGR: -89.17%
Diluted EPS 5Y CAGR: -53.06%
Diluted EPS 10Y CAGR: -56.79%
Recent Earnings Call Insights
Q3 2024 Results:

UDENYCA revenue grew 100% year-over-year to $66 million, maintaining its #2 position in the pegfilgrastim market with a 28% market share ([source], [source]).
Temporary supply interruption for UDENYCA, but packaging is resuming with 120,000 units expected to be completed over the next 5 weeks ([source], [source]).
Advancing immune-oncology pipeline, including Casdozokitug and CHS-114 ([source], [source]).
LOQTORZI saw 54% quarter-over-quarter revenue growth ([source], [source]).
Focused on disciplined financial management, reducing operating expenses, and improving gross margins ([source]).
👍️0
Shareing is winning Shareing is winning 2 월 전
If this drops below $1.75 I'm in for another bunch maybe 500,000 just for Suppository's sake!
👍️0
Shareing is winning Shareing is winning 2 월 전
https://ih.advfn.com/stock-market/NASDAQ/coherus-biosciences-CHRS/stock-news/95025208/form-defa14a-additional-definitive-proxy-solicit
👍️0
Shareing is winning Shareing is winning 2 월 전
Pulled in 100,000 yesterday morning at 1.25 thought about selling half when it was at 2.35 range should have and waited to restock this afternoon.
when this hits 2.75 i am out!!!!!!!!!!
👍️0
mugs57 mugs57 2 월 전
isn't the rule that a stock will run for 3 days before it takes a breather??
the cap value before getting the 500 mil was like 130 mil - we should at least see 2-3x the 1.30 starting price! go $CHRS!
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
CHRS MONSTER BIO
👍️0
tw0122 tw0122 2 월 전
Back out 1.97
👍️0
tw0122 tw0122 2 월 전
Added 1.80s for the next flip
👍️0
tw0122 tw0122 2 월 전
Back in 1.90
👍️0
mugs57 mugs57 2 월 전
45000 call options at jan $1 strike! you think someone knew something coming?? with this influx of cash stock could go to $5!!!
👍️0
tw0122 tw0122 2 월 전
Keep it simple $1.80s flippped at $1.96. Profit zone is $1.90- )2.85 expect some more lifting. Good luck 
👍️0
tw0122 tw0122 2 월 전
Nice pick with the news getting rid of debt
f., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company NASDAQ: CHRS,) today announced that it has entered into an asset purchase agreement (the Agreement) dated December 2, 2024, with Intas Pharmaceuticals Ltd. (Intas) for the divestiture of the UDENYCA (pegfilgrastim-cbqv) franchise for up to $558.4 million. This includes an upfront payment of $483.4 million, to be adjusted for inventory at close, and $75.0 million in potential net sales milestone payments. Coherus plans to use a portion of the transaction proceeds to fully repay the entirety of the Company’s $230.0 million in existing convertible notes due April 2026 and $49.1 million to buy-out certain royalty obligations related to UDENYCA.“The proposed divestiture of UDENYCA represents the successful execution of our strategy to focus R&D and commercial resources on Coherus’ innovative immuno-oncology portfolio and to strengthen our financial position,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “We have created significant value with our UDENYCA franchise, and this proposed transaction allows us to monetize that value in order to maximize the opportunity ahead for LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor with growing sales and the only FDA-approved treatment for nasopharyngeal carcinoma (NPC), allowing us to accelerate and advance the development of our I-O pipeline in combination with LOQTORZI.”“In addition, by paying off our convertible notes in their entirety, we will significantly improve our capital structure and align our operational footprint with our strategic focus. As we enter this new phase of growth, we are well positioned to drive significant value for both patients and shareholders as we advance our mission to extend cancer patient survival.”
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
CHRS RUNNING
👍️0
glenn1919 glenn1919 2 월 전
CHRS.....................................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 월 전
CHRS............................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 월 전
CHRS........................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
mugs57 mugs57 2 월 전
anyone have any idea why the steady rise with volume?
👍️0
glenn1919 glenn1919 2 월 전
CHRS.......................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 월 전
CHRS..................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
The GidDy uP Kid The GidDy uP Kid 2 월 전
Nice day todaY...
👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
https://schrts.co/sMeAHIGh

👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
 daily psar fliPPed to the Bullish Buy Side…
👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
76 after hours… 
👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
 aDDing… 
👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
 back to greeN… 
👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
Nice daily Bullish Engulfing candle… 
https://schrts.co/TkiuQvJe
👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
inverted HammeR off the lower Keltner line, with the daily psar flip to the Bullish side quickly approaching; furthermore, pinching in here on the pincher 🤏 …  
https://schrts.co/IJcPqwzg
👍️0
The GidDy uP Kid The GidDy uP Kid 3 월 전
...
👍️0
boytroy88 boytroy88 3 월 전
It's even lower now. ☹️
👍️0
Monksdream Monksdream 4 월 전
CHRS new 52 week low
👍️0
Monksdream Monksdream 6 월 전
CHRS under $2
👍️0
Monksdream Monksdream 6 월 전
CHRS under $2
👍️0
glenn1919 glenn1919 6 월 전
CHRS...................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 월 전
CHRS under $3
👍️0
frans frans 11 월 전
short interest about 28.000.000 milj.up 7% today
👍️0
Mile High Marauder Mile High Marauder 11 월 전
Here is short interest link

https://www.nasdaq.com/market-activity/stocks/chrs/short-interest
👍️0
frans frans 11 월 전
you know how many shorts we have here to cover ????
my last buy was 2.08
👍️0
Mile High Marauder Mile High Marauder 11 월 전
I think selling these non core assets, with the probability of selling more has greatly diminished the need to raise money and has put some pressure on the shorts to cover some of this massive short. IMO
👍️ 1
frans frans 12 월 전
Coherus’ oncology assets include the UDENYCA® (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; LOQTORZI™ (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor; and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates.

Closing is anticipated in from jan 22
👍️0
Mile High Marauder Mile High Marauder 12 월 전
What fda news are u looking for?
👍️0

최근 히스토리

Delayed Upgrade Clock